Actelion Pharmaceuticals Ltd

Daniel Trachsel

Christoph Boss

Thierry Sifferlen

Hamed Aissaoui

Ralf Koberstein

Markus Gude

Romain Siegrist

David Lehmann

David Lehman

The invention relates to novel 2-aza-bicyclo[3.1.0]hexane derivatives of Formula (I) wherein A, B, n and Rare as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists. 

2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists

The invention relates to 2-aza-bicyclo[3.3.0]octane derivatives of Formula (I) wherein A, B, and Rare as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists. 

2-aza-bicyclo[3.3.0]octane derivatives

The invention relates to novel 2-aza-bicyclo[2.2.1]heptane derivatives of formula (I), wherein A, B, n and Rare as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.

2-aza-bicyclo[2.2.1]heptane derivatives

The invention relates to novel trans-3-aza-bicyclo[3.1.0]hexane derivatives of formula (I), wherein A, B, n and Rare as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists. 

Growing community of inventors

Bubendorf, Switzerland

Daniel Trachsel